IN BRIEF: Syncona invests GBP18 million in Beacon financing round
8th Jan 2026 15:45
Syncona Ltd - London-based investor in life science companies - Invests USD24.5 million in ophthalmic gene therapy company Beacon Therapeutics' USD75 million Series C financing. Says the financing round was oversubscribed and brings Beacon's total funding raised so far to approximately USD367 million. Beacon will use the proceeds "to progress commercialisation plans" and to complete the development of its lead programme laru-zova, "a potential best-in-class gene therapy" for X-linked retinitis pigmentosa, Syncona says. Syncona's holding value of Beacon will now be USD237.6 million, including new capital invested, and it will hold a 38.4% ownership stake. Read More